Skip to main content
NCBI home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1996 Jun;164(6):502–509.

Magnetic resonance imaging of multiple sclerosis lesions. Measuring outcome in treatment trials.

J H Simon 1
PMCID: PMC1303626  PMID: 8764625

Abstract

Magnetic resonance-based measures of disease activity and progression are now routinely used in definitive phase III treatment trials of multiple sclerosis as important secondary outcome measures because they provide quantitative and objective confirmation of the primary clinical outcome measures. Magnetic resonance-based activity measures can also be used as an efficient mechanism for screening therapies in phase I and II trials. In this review I consider the natural history of multiple sclerosis lesions and the relationships between magnetic resonance measures and clinical observations of disease as the basis for the use of magnetic resonance markers in current and future treatment trials.

Full text

PDF
502

Images in this article

504Figure 3.
on p.504
504Figure 4.
on p.504

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnold D. L., Riess G. T., Matthews P. M., Francis G. S., Collins D. L., Wolfson C., Antel J. P. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol. 1994 Jul;36(1):76–82. doi: 10.1002/ana.410360115. [DOI] [PubMed] [Google Scholar]
  2. BRAIN R. Posture. Br Med J. 1959 Jun 13;1(5136):1489–1491. doi: 10.1136/bmj.1.5136.1489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barkhof F., Scheltens P., Frequin S. T., Nauta J. J., Tas M. W., Valk J., Hommes O. R. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR Am J Roentgenol. 1992 Nov;159(5):1041–1047. doi: 10.2214/ajr.159.5.1414773. [DOI] [PubMed] [Google Scholar]
  4. Barnard R. O., Triggs M. Corpus callosum in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1974 Nov;37(11):1259–1264. doi: 10.1136/jnnp.37.11.1259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Barnes D., Munro P. M., Youl B. D., Prineas J. W., McDonald W. I. The longstanding MS lesion. A quantitative MRI and electron microscopic study. Brain. 1991 Jun;114(Pt 3):1271–1280. doi: 10.1093/brain/114.3.1271. [DOI] [PubMed] [Google Scholar]
  6. Davie C. A., Hawkins C. P., Barker G. J., Brennan A., Tofts P. S., Miller D. H., McDonald W. I. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain. 1994 Feb;117(Pt 1):49–58. doi: 10.1093/brain/117.1.49. [DOI] [PubMed] [Google Scholar]
  7. Dousset V., Brochet B., Vital A., Gross C., Benazzouz A., Boullerne A., Bidabe A. M., Gin A. M., Caille J. M. Lysolecithin-induced demyelination in primates: preliminary in vivo study with MR and magnetization transfer. AJNR Am J Neuroradiol. 1995 Feb;16(2):225–231. [PMC free article] [PubMed] [Google Scholar]
  8. Dousset V., Grossman R. I., Ramer K. N., Schnall M. D., Young L. H., Gonzalez-Scarano F., Lavi E., Cohen J. A. Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology. 1992 Feb;182(2):483–491. doi: 10.1148/radiology.182.2.1732968. [DOI] [PubMed] [Google Scholar]
  9. Filippi M., Horsfield M. A., Morrissey S. P., MacManus D. G., Rudge P., McDonald W. I., Miller D. H. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology. 1994 Apr;44(4):635–641. doi: 10.1212/wnl.44.4.635. [DOI] [PubMed] [Google Scholar]
  10. Filippi M., Paty D. W., Kappos L., Barkhof F., Compston D. A., Thompson A. J., Zhao G. J., Wiles C. M., McDonald W. I., Miller D. H. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology. 1995 Feb;45(2):255–260. doi: 10.1212/wnl.45.2.255. [DOI] [PubMed] [Google Scholar]
  11. Frank J. A., Stone L. A., Smith M. E., Albert P. S., Maloni H., McFarland H. F. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials. Ann Neurol. 1994;36 (Suppl):S86–S90. doi: 10.1002/ana.410360719. [DOI] [PubMed] [Google Scholar]
  12. Gass A., Barker G. J., Kidd D., Thorpe J. W., MacManus D., Brennan A., Tofts P. S., Thompson A. J., McDonald W. I., Miller D. H. Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol. 1994 Jul;36(1):62–67. doi: 10.1002/ana.410360113. [DOI] [PubMed] [Google Scholar]
  13. Gilbert J. J., Sadler M. Unsuspected multiple sclerosis. Arch Neurol. 1983 Sep;40(9):533–536. doi: 10.1001/archneur.1983.04050080033003. [DOI] [PubMed] [Google Scholar]
  14. Goodkin D. E., Hertsgaard D., Rudick R. A. Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials. Arch Neurol. 1989 Oct;46(10):1107–1112. doi: 10.1001/archneur.1989.00520460093019. [DOI] [PubMed] [Google Scholar]
  15. Goodkin D. E. Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis. West J Med. 1994 Sep;161(3):292–298. [PMC free article] [PubMed] [Google Scholar]
  16. Grossman R. I., Braffman B. H., Brorson J. R., Goldberg H. I., Silberberg D. H., Gonzalez-Scarano F. Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. Radiology. 1988 Oct;169(1):117–122. doi: 10.1148/radiology.169.1.3420246. [DOI] [PubMed] [Google Scholar]
  17. Grossman R. I., Lenkinski R. E., Ramer K. N., Gonzalez-Scarano F., Cohen J. A. MR proton spectroscopy in multiple sclerosis. AJNR Am J Neuroradiol. 1992 Nov-Dec;13(6):1535–1543. [PMC free article] [PubMed] [Google Scholar]
  18. Harris J. O., Frank J. A., Patronas N., McFarlin D. E., McFarland H. F. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol. 1991 May;29(5):548–555. doi: 10.1002/ana.410290515. [DOI] [PubMed] [Google Scholar]
  19. Hiehle J. F., Jr, Grossman R. I., Ramer K. N., Gonzalez-Scarano F., Cohen J. A. Magnetization transfer effects in MR-detected multiple sclerosis lesions: comparison with gadolinium-enhanced spin-echo images and nonenhanced T1-weighted images. AJNR Am J Neuroradiol. 1995 Jan;16(1):69–77. [PMC free article] [PubMed] [Google Scholar]
  20. Isaac C., Li D. K., Genton M., Jardine C., Grochowski E., Palmer M., Kastrukoff L. F., Oger J., Paty D. W. Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology. 1988 Oct;38(10):1511–1515. doi: 10.1212/wnl.38.10.1511. [DOI] [PubMed] [Google Scholar]
  21. Jacobs L. D., Cookfair D. L., Rudick R. A., Herndon R. M., Richert J. R., Salazar A. M., Fischer J. S., Goodkin D. E., Granger C. V., Simon J. H. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). Mult Scler. 1995 Jun;1(2):118–135. doi: 10.1177/135245859500100210. [DOI] [PubMed] [Google Scholar]
  22. Jacobs L. D., Cookfair D. L., Rudick R. A., Herndon R. M., Richert J. R., Salazar A. M., Fischer J. S., Goodkin D. E., Granger C. V., Simon J. H. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol. 1996 Mar;39(3):285–294. doi: 10.1002/ana.410390304. [DOI] [PubMed] [Google Scholar]
  23. Jacobs L., Johnson K. P. A brief history of the use of interferons as treatment of multiple sclerosis. Arch Neurol. 1994 Dec;51(12):1245–1252. doi: 10.1001/archneur.1994.00540240089022. [DOI] [PubMed] [Google Scholar]
  24. Katz D., Taubenberger J. K., Cannella B., McFarlin D. E., Raine C. S., McFarland H. F. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol. 1993 Nov;34(5):661–669. doi: 10.1002/ana.410340507. [DOI] [PubMed] [Google Scholar]
  25. Kermode A. G., Thompson A. J., Tofts P., MacManus D. G., Kendall B. E., Kingsley D. P., Moseley I. F., Rudge P., McDonald W. I. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain. 1990 Oct;113(Pt 5):1477–1489. doi: 10.1093/brain/113.5.1477. [DOI] [PubMed] [Google Scholar]
  26. Kermode A. G., Tofts P. S., Thompson A. J., MacManus D. G., Rudge P., Kendall B. E., Kingsley D. P., Moseley I. F., du Boulay E. P., McDonald W. I. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology. 1990 Feb;40(2):229–235. doi: 10.1212/wnl.40.2.229. [DOI] [PubMed] [Google Scholar]
  27. Kidd D., Thorpe J. W., Thompson A. J., Kendall B. E., Moseley I. F., MacManus D. G., McDonald W. I., Miller D. H. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology. 1993 Dec;43(12):2632–2637. doi: 10.1212/wnl.43.12.2632. [DOI] [PubMed] [Google Scholar]
  28. Kikinis R., Shenton M. E., Gerig G., Martin J., Anderson M., Metcalf D., Guttmann C. R., McCarley R. W., Lorensen W., Cline H. Routine quantitative analysis of brain and cerebrospinal fluid spaces with MR imaging. J Magn Reson Imaging. 1992 Nov-Dec;2(6):619–629. doi: 10.1002/jmri.1880020603. [DOI] [PubMed] [Google Scholar]
  29. Koopmans R. A., Li D. K., Oger J. J., Kastrukoff L. F., Jardine C., Costley L., Hall S., Grochowski E. W., Paty D. W. Chronic progressive multiple sclerosis: serial magnetic resonance brain imaging over six months. Ann Neurol. 1989 Aug;26(2):248–256. doi: 10.1002/ana.410260211. [DOI] [PubMed] [Google Scholar]
  30. Koopmans R. A., Li D. K., Oger J. J., Mayo J., Paty D. W. The lesion of multiple sclerosis: imaging of acute and chronic stages. Neurology. 1989 Jul;39(7):959–963. doi: 10.1212/wnl.39.7.959. [DOI] [PubMed] [Google Scholar]
  31. Kurtzke J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444–1452. doi: 10.1212/wnl.33.11.1444. [DOI] [PubMed] [Google Scholar]
  32. Larsson H. B., Christiansen P., Jensen M., Frederiksen J., Heltberg A., Olesen J., Henriksen O. Localized in vivo proton spectroscopy in the brain of patients with multiple sclerosis. Magn Reson Med. 1991 Nov;22(1):23–31. doi: 10.1002/mrm.1910220104. [DOI] [PubMed] [Google Scholar]
  33. McFarland H. F., Frank J. A., Albert P. S., Smith M. E., Martin R., Harris J. O., Patronas N., Maloni H., McFarlin D. E. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol. 1992 Dec;32(6):758–766. doi: 10.1002/ana.410320609. [DOI] [PubMed] [Google Scholar]
  34. Miller D. H., Albert P. S., Barkhof F., Francis G., Frank J. A., Hodgkinson S., Lublin F. D., Paty D. W., Reingold S. C., Simon J. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol. 1996 Jan;39(1):6–16. doi: 10.1002/ana.410390104. [DOI] [PubMed] [Google Scholar]
  35. Miller D. H., Barkhof F., Nauta J. J. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain. 1993 Oct;116(Pt 5):1077–1094. doi: 10.1093/brain/116.5.1077. [DOI] [PubMed] [Google Scholar]
  36. Miller D. H., Rudge P., Johnson G., Kendall B. E., Macmanus D. G., Moseley I. F., Barnes D., McDonald W. I. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain. 1988 Aug;111(Pt 4):927–939. doi: 10.1093/brain/111.4.927. [DOI] [PubMed] [Google Scholar]
  37. Mitchell J. R., Karlik S. J., Lee D. H., Fenster A. Computer-assisted identification and quantification of multiple sclerosis lesions in MR imaging volumes in the brain. J Magn Reson Imaging. 1994 Mar-Apr;4(2):197–208. doi: 10.1002/jmri.1880040218. [DOI] [PubMed] [Google Scholar]
  38. Narayana P. A., Wolinsky J. S., Jackson E. F., McCarthy M. Proton MR spectroscopy of gadolinium-enhanced multiple sclerosis plaques. J Magn Reson Imaging. 1992 May-Jun;2(3):263–270. doi: 10.1002/jmri.1880020303. [DOI] [PubMed] [Google Scholar]
  39. Nauta J. J., Thompson A. J., Barkhof F., Miller D. H. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs. J Neurol Sci. 1994 Mar;122(1):6–14. doi: 10.1016/0022-510x(94)90045-0. [DOI] [PubMed] [Google Scholar]
  40. Nesbit G. M., Forbes G. S., Scheithauer B. W., Okazaki H., Rodriguez M. Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology. 1991 Aug;180(2):467–474. doi: 10.1148/radiology.180.2.2068314. [DOI] [PubMed] [Google Scholar]
  41. Newcombe J., Hawkins C. P., Henderson C. L., Patel H. A., Woodroofe M. N., Hayes G. M., Cuzner M. L., MacManus D., du Boulay E. P., McDonald W. I. Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissue. Brain. 1991 Apr;114(Pt 2):1013–1023. doi: 10.1093/brain/114.2.1013. [DOI] [PubMed] [Google Scholar]
  42. Noseworthy J. H., Vandervoort M. K., Wong C. J., Ebers G. C. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology. 1990 Jun;40(6):971–975. doi: 10.1212/wnl.40.6.971. [DOI] [PubMed] [Google Scholar]
  43. Paty D. W., Li D. K. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology. 1993 Apr;43(4):662–667. doi: 10.1212/wnl.43.4.662. [DOI] [PubMed] [Google Scholar]
  44. Paty D. W., Li D. K., Oger J. J., Kastrukoff L., Koopmans R., Tanton E., Zhao G. J. Magnetic resonance imaging in the evaluation of clinical trials in multiple sclerosis. Ann Neurol. 1994;36 (Suppl):S95–S96. doi: 10.1002/ana.410360721. [DOI] [PubMed] [Google Scholar]
  45. Pelletier J., Habib M., Lyon-Caen O., Salamon G., Poncet M., Khalil R. Functional and magnetic resonance imaging correlates of callosal involvement in multiple sclerosis. Arch Neurol. 1993 Oct;50(10):1077–1082. doi: 10.1001/archneur.1993.00540100066018. [DOI] [PubMed] [Google Scholar]
  46. Phadke J. G., Best P. V. Atypical and clinically silent multiple sclerosis: a report of 12 cases discovered unexpectedly at necropsy. J Neurol Neurosurg Psychiatry. 1983 May;46(5):414–420. doi: 10.1136/jnnp.46.5.414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Prineas J. W., Barnard R. O., Revesz T., Kwon E. E., Sharer L., Cho E. S. Multiple sclerosis. Pathology of recurrent lesions. Brain. 1993 Jun;116(Pt 3):681–693. doi: 10.1093/brain/116.3.681. [DOI] [PubMed] [Google Scholar]
  48. Rao S. M., Leo G. J., Haughton V. M., St Aubin-Faubert P., Bernardin L. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology. 1989 Feb;39(2 Pt 1):161–166. doi: 10.1212/wnl.39.2.161. [DOI] [PubMed] [Google Scholar]
  49. Revesz T., Kidd D., Thompson A. J., Barnard R. O., McDonald W. I. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain. 1994 Aug;117(Pt 4):759–765. doi: 10.1093/brain/117.4.759. [DOI] [PubMed] [Google Scholar]
  50. Richards T. L. Proton MR spectroscopy in multiple sclerosis: value in establishing diagnosis, monitoring progression, and evaluating therapy. AJR Am J Roentgenol. 1991 Nov;157(5):1073–1078. doi: 10.2214/ajr.157.5.1927795. [DOI] [PubMed] [Google Scholar]
  51. Simon J. H., Schiffer R. B., Rudick R. A., Herndon R. M. Quantitative determination of MS-induced corpus callosum atrophy in vivo using MR imaging. AJNR Am J Neuroradiol. 1987 Jul-Aug;8(4):599–604. [PMC free article] [PubMed] [Google Scholar]
  52. Smith M. E., Stone L. A., Albert P. S., Frank J. A., Martin R., Armstrong M., Maloni H., McFarlin D. E., McFarland H. F. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol. 1993 May;33(5):480–489. doi: 10.1002/ana.410330511. [DOI] [PubMed] [Google Scholar]
  53. Stone L. A., Albert P. S., Smith M. E., DeCarli C., Armstrong M. R., McFarlin D. E., Frank J. A., McFarland H. F. Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis. Neurology. 1995 Oct;45(10):1808–1814. doi: 10.1212/wnl.45.10.1808. [DOI] [PubMed] [Google Scholar]
  54. Stone L. A., Frank J. A., Albert P. S., Bash C., Smith M. E., Maloni H., McFarland H. F. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol. 1995 May;37(5):611–619. doi: 10.1002/ana.410370511. [DOI] [PubMed] [Google Scholar]
  55. Thompson A. J., Kermode A. G., MacManus D. G., Kendall B. E., Kingsley D. P., Moseley I. F., McDonald W. I. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ. 1990 Mar 10;300(6725):631–634. doi: 10.1136/bmj.300.6725.631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Thompson A. J., Kermode A. G., Wicks D., MacManus D. G., Kendall B. E., Kingsley D. P., McDonald W. I. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol. 1991 Jan;29(1):53–62. doi: 10.1002/ana.410290111. [DOI] [PubMed] [Google Scholar]
  57. Thompson A. J., Miller D., Youl B., MacManus D., Moore S., Kingsley D., Kendall B., Feinstein A., McDonald W. I. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology. 1992 Jan;42(1):60–63. doi: 10.1212/wnl.42.1.60. [DOI] [PubMed] [Google Scholar]
  58. Uhlenbrock D., Sehlen S. The value of T1-weighted images in the differentiation between MS, white matter lesions, and subcortical arteriosclerotic encephalopathy (SAE). Neuroradiology. 1989;31(3):203–212. doi: 10.1007/BF00344344. [DOI] [PubMed] [Google Scholar]
  59. Weinshenker B. G., Ebers G. C. The natural history of multiple sclerosis. Can J Neurol Sci. 1987 Aug;14(3):255–261. doi: 10.1017/s0317167100026573. [DOI] [PubMed] [Google Scholar]
  60. Weinstock-Guttman B., Ransohoff R. M., Kinkel R. P., Rudick R. A. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol. 1995 Jan;37(1):7–15. doi: 10.1002/ana.410370105. [DOI] [PubMed] [Google Scholar]
  61. Whitaker J. N., McFarland H. F., Rudge P., Reingold S. C. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler. 1995 Apr;1(1):37–47. doi: 10.1177/135245859500100107. [DOI] [PubMed] [Google Scholar]
  62. Wiebe S., Lee D. H., Karlik S. J., Hopkins M., Vandervoort M. K., Wong C. J., Hewitt L., Rice G. P., Ebers G. C., Noseworthy J. H. Serial cranial and spinal cord magnetic resonance imaging in multiple sclerosis. Ann Neurol. 1992 Nov;32(5):643–650. doi: 10.1002/ana.410320507. [DOI] [PubMed] [Google Scholar]
  63. Willoughby E. W., Grochowski E., Li D. K., Oger J., Kastrukoff L. F., Paty D. W. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol. 1989 Jan;25(1):43–49. doi: 10.1002/ana.410250107. [DOI] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES